Merit Financial Group
RCKT icon

Merit Financial Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Merit Financial Group’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-19,360
Closed -$66.2K – 2547
2026
Q2 		$66.2K Sell
19,360
-2,956
-13% -$9.8K ﹤0.01% 2266
2026
Q1 		$79.9K Buy
+22,316
New +$88.7K ﹤0.01% 2032

Other funds holding RCKT

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Monaco Asset Management
Monaco Asset Management Monaco $818M AUM 32.61% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Merit Financial Group's RCKT Position: Q3 2026 in Review

Merit Financial Group sold out of Rocket Pharmaceuticals (RCKT) in Q3 2026, closing a stake of 19,360 shares — an estimated $66.2K sold.

Merit Financial Group first reported a position in RCKT in Q1 2026 and held it in 2 quarters. The position peaked at $79.9K in Q1 2026. 116 funds tracked by Wall St. Rank hold RCKT as of Q3 2026.

  • Merit Financial Group reported no remaining Rocket Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Merit Financial Group sold 19,360 Rocket Pharmaceuticals shares in Q3 2026, an estimated $66.2K.
  • Merit Financial Group first reported a position in Rocket Pharmaceuticals in Q1 2026 and held it in 2 quarters.
  • Merit Financial Group's Rocket Pharmaceuticals position peaked at $79.9K in Q1 2026.
  • 116 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2026.

Based on Merit Financial Group's 13F filing for Q3 2026, filed 6 Nov 2026.